Publications by authors named "B A Ference"
Article Synopsis
- * Keeping LDL cholesterol levels low reduces the number of LDL particles in arteries, which slows atherosclerosis progression and lowers lifetime ASCVD risk.
- * The concept of LDL cumulative exposure, combining the amount and duration of LDL levels, serves as a unique risk marker for cardiovascular events and can guide strategies for ASCVD prevention in clinical practice.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Stephen J Nicholls Adam J Nelson Marc Ditmarsch John J P Kastelein Christie M Ballantyne Brian A Ference
Am Heart J
August 2024
Article Synopsis
- - Obicetrapib is a new medication that lowers harmful LDL cholesterol and increases beneficial HDL cholesterol, potentially helping patients with high cholesterol levels who don’t respond to standard treatments.
- - The BROADWAY and BROOKLYN trials are ongoing studies testing the effectiveness and safety of obicetrapib in patients with cardiovascular disease or genetic high cholesterol issues; over 2,500 participants are involved.
- - Results from these trials, which will examine various cholesterol-related markers and safety concerns, are expected in 2024 and could support the use of obicetrapib in high-risk patient populations.
Article Synopsis
- The use of drugs to lower LDL cholesterol (LDL-C) has significantly decreased the risk of heart disease, but some cardiovascular risk remains.
- Elevated triglycerides (TGs) and TG-rich lipoproteins are linked to increased cardiovascular risk, highlighting the need to address these factors.
- New treatments targeting apolipoprotein C-III (apoC-III), which plays a crucial role in TG metabolism, show promise in further reducing triglyceride levels and associated heart disease risk.
Article Synopsis
- In 2022, the European Atherosclerosis Society released a consensus statement highlighting the link between lipoprotein(a) [Lp(a)] levels and an increased risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
- A new risk calculator was introduced to help assess an individual's lifetime risk for ASCVD, particularly noting that those with high Lp(a) levels may be at greater risk than previously understood.
- The statement also offers practical guidance for managing cardiovascular risk based on Lp(a) levels and addresses common questions regarding Lp(a) measurement and treatment options in everyday clinical practice.
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD.
View Article and Find Full Text PDF